2025 China Drug Catalog Boosts Access with 114 ...

By HEOR Staff Writer

December 9, 2025

Expansion of Coverage in the 2025 National Basic Medical Insurance Drug Catalog In this update we highlight updates and implications of the 2025 Nationa...
Repurposing Off-Patent Medicines: Insights from the EU Pilot Initiative
CTX310 Lipid Disorder: Phase 1 Trial Shows Promising LDL and Triglyceride Red...
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adu...
Key Decisions on Health Technology Assessment at ACP124: Implications for Rar...
Rare Medications Coverage in the Netherlands: Price Reductions Required
Sanofi’s Rilzabrutinib Receives Orphan Designation for IgG4-Related Dis...
Most Expensive Drugs 2025: Trends and Implications in US Pharma Pricing
Efficacy of Ultomiris Pediatric TMA Treatment
Blinatumomab Benefit Assessment for ALL and Health Economics
Tolebrutinib MS Analysis: Evaluating Economic Impact in SPMS
Allopurinol Designated an Orphan Drug for Marfan Syndrome
NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment...